Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NGEN with free AI briefings, catalyst countdowns, and dilution alerts.

NGEN · NervGen Pharma Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$86.8M Cash on Hand
40.6mo Cash Runway
0% Short Interest
$10 Analyst Target (1)
Follow NGEN by email Get an email when NGEN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NGEN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
NVG-291 Chronic Spinal Cord Injury Phase 3 · NCT07799532 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NGEN holds $86.8M in cash and short-term investments and burns about $6.4M/quarter from operations, an estimated runway of 40.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NGEN files for a raise →

👥 Who Owns NGEN

Insiders Form 4 data not loaded yet Institutions (75 holders) 11.9% Public and other holders 88.1%
HolderTypeShares% of sharesAs of
Empery Asset Management, LP Institution (13F) 3,308,973 4.15% 2026-09-30
Rock Springs Capital Management, LP Institution (13F) 1,208,231 1.52% 2026-09-30
Valley Forge Investment Consultants, Inc Institution (13F) 834,156 1.05% 2026-09-30
DAFNA Capital Management, LLC Institution (13F) 810,862 1.02% 2026-09-30
Marshall Wace LLP Institution (13F) 617,253 0.77% 2026-09-30
LMR Partners LLP Institution (13F) 550,000 0.69% 2026-09-30
Ghisallo Capital Management, LLC Institution (13F) 500,000 0.63% 2026-09-30
Two Sigma Investments, LP Institution (13F) 463,494 0.58% 2026-09-30
UBS Group AG Institution (13F) 284,572 0.36% 2026-09-30
Woodline Partners LP Institution (13F) 250,500 0.31% 2026-09-30

Share count 79,649,257 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NGEN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NGEN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.